New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis [Corrigendum]
Frati F, Cecchi L, Scala E, Ridolo E, Dell’Albani I, Makrì E, Pajno GB, Incorvaia C. Biologics: Targets and Therapy. 2014;8:221–226.
On page 223, Figure 1 should be replaced with the revised version as shown below:
On page 224, line 4 in the left column, "many" should be replaced with "all".
On page 224, line 7 in the left column, "but only the major allergen Phl p 5 is measured in μg" should be replaced with "such as group 1 and group 5 allergens (Figure1, Table 2)".
On page 224, line 9 in the left column, the reference to "(Figure 1)" should be removed.
Read the original article
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]